Lv4
672 积分 2024-06-05 加入
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed
40分钟前
已完结
Der Rhesusfaktor und seine klinische Bedeutung
3小时前
待确认
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis
1个月前
已完结
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
1个月前
已完结
[Guidelines for the early evaluation and management of chronic kidney disease in China]
4个月前
已完结
Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0
5个月前
已完结
Mechanisms Underlying Delayed loss of HBeAg and HBV DNA Following HBsAg Seroclearance in PEG-IFNα Treated Patients of chronic hepatitis B
6个月前
已完结
[HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study]
7个月前
已完结
The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions
9个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
9个月前
已完结
皖公网安备34019202002308
